Abstract:Background: Benzodiazepines have long held a leading position in medical therapeutics, known for their multiple common therapeutic properties and primarily being prescribed for anxiety and insomnia. However, their lack of specificity and various side effects have led to a reevaluation of their long-term use, resulting in a rapid growth in the literature focusing on targeted therapies. Areas of uncertainty: Despite many efforts, uncertainties persist and there are heterogeneous findings across studies regarding the pharmacological effects attributed to gamma-aminobutyric acid type A (GABAA) receptor subunits. Selective compounds targeting GABAA receptor alpha subunits are currently under active research and definitive conclusions have not been reached yet. Some compounds have not progressed to clinical trials, while others, if advanced, have been halted. These challenges emphasize the difficulty in translating preclinical findings into clinical use. Data sources: A literature review was conducted using the PubMed database, searching for articles discussing GABAA receptor subunits. The search was refined by including only selective compounds with potential anxiolytic and cognitive enhancement properties. Results: Findings reveal compounds with promising anxiolytic and antidepressant effects with minimal sedation and absence of tolerance development. Moreover, some compounds show potential in alleviating cognitive dysfunction. There is a broad spectrum of potential therapeutic applications for selective compounds, ranging from neurological disorders such as epilepsy and neuropathic pain to cognitive dysfunction-related conditions. Currently, the leading selective compounds with the most promising results in ongoing clinical trials are basmisanil and darigabat. Basmisanil holds further exploration potential in the treatment of cognitive impairment and related conditions, while darigabat shows progress in the advancement of adjunctive therapy of focal onset seizures and for the treatment of panic disorder, respectively. Conclusions: Future drug discovery efforts are encouraged to focus on positive allosteric modulators that selectively target the α2, α3 subunits and negative/positive allosteric modulators that target the α5 subunit of the GABAA receptor. The pursuit of ligands possessing only anxiolytic effects or those enhancing cognition continues to be an important focus for future research, with promising advancements depicted in recent studies.

The Gamma-Aminobutyric Acid B Receptor in Depression and Reward

Unravelling biological roles and mechanisms of GABABR on addiction and depression through mood and memory disorders

Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit–Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice

GABAA receptors as targets for treating affective and cognitive symptoms of depression

Evolution of Neurotransmitter Gamma-Aminobutyric Acid, Glutamate and Their Receptors

GABA(A) receptor diversity and pharmacology

Targeting GABAAR-Associated Proteins: New Modulators, Labels and Concepts

Significance of GABAA Receptors in the Development of Some Neuropsychiatric Diseases

The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs

The Role of Dopamine Receptor Dimer Complexes in the Pathogenesis of Depression

The brain galanin receptors: targets for novel antidepressant drugs

Stable High Expression of Human Gamma-Aminobutyric Acida Receptors Composed of Alpha and Beta Subünits

Analysis of the functional role and mRNA expression of GABA B R in the nucleus accumbens of cocaine-addicted rats

New Insights Into Pharmacology of GABAA Receptor Alpha Subunits-Selective Modulators

Development of Antidepressant Drugs Through Targeting Α4β2-Nicotinic Acetylcholine Receptors

Quantifying GABA in Addiction: A Review of Proton Magnetic Resonance Spectroscopy Studies

Heteromeric GABA<sub>A</sub>receptor structures in positively-modulated active states

Therapeutic Anti-Depressant Potential of Microbial GABA Produced by Lactobacillus rhamnosus Strains for GABAergic Signaling Restoration and Inhibition of Addiction-Induced HPA Axis Hyperactivity

Role of α1-GABAA receptors in the serotonergic dorsal raphe nucleus in models of opioid reward, anxiety, and depression

The emergence of antidepressant drugs targeting GABAA receptors: A concise review

VTA GABA Neurons at the Interface of Stress and Reward